A recent unpublished study investigating the effects of several drugs and cancer risk using a target trial emulation framework, found that Captopril, the generic name of an ACE inhibitor, was associated with an increased colorectal cancer risk (HR = 2.15, 95% CI = [1.81, 2.57]), as compared to control drugs (medRxiv 2024.05.29.24308170). Here, ACE is linked to colorectal cancer.